From Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), College of Medicine, Mayo Clinic, Rochester, MN.
Address reprint requests to Dr. Camilleri at the Mayo Clinic, Charlton 8-110, 200 First St. SW, Rochester, MN 55905, or at [email protected].
Dr. Camilleri reports receiving consulting fees from Takeda Pharmaceuticals USA, Albany Molecular Research, BioKier, Theravance, Alkermes, ARYx Therapeutics, AstraZeneca, Domain Therapeutics, Ironwood Pharmaceuticals, Tranzyme, and NPS Pharmaceuticals; receiving grant support from Rose Pharma, Albireo, Tsumura, Second Genome, SK Life Science, Salix Pharmaceuticals, and Rhythm through his institution; being a coinventor of a patent related to enteric delivery of chenodeoxycholic acid for constipation; and receiving royalties from EnteroMedics for licensed technology related to vagal-stimulation treatment of obesity. No other potential conflict of interest relevant to this article was reported.
Disclosure forms provided by the author are available with the full text of this article at NEJM.org.
